Information;Judgment — ECLI:EU:T:2020:547
Date: 2020-11-18
Language of the case: English
Court formation: Third Chamber
Subject matter: Trade marks;Intellectual, industrial and commercial property
Procedure: Action for annulment - unfounded
Origin: France

Judgment of the General Court (Third Chamber) of 18 November 2020 – Allergan Holdings France v EUIPO – Dermavita (JUVEDERM ULTRA) (Case T‑664/19) (EU trade mark – Revocation proceedings – EU word mark JUVEDERM ULTRA – Genuine use of the mark – Use in connection with the goods in respect of which the mark was registered – Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001)) 1. EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Proof of use – Burden of proof (Council Regulation No 207/2009, Art. 51) (see para. 18) 2. EU trade mark – Surrender, revocation and invalidity – Causes of revocation – Absence of genuine use of a trade mark – Word mark JUVEDERM ULTRA (Council Regulation No 207/2009, Art. 15(1)(a)) (see paras 19, 20) Re: Action brought against the decision of the Fourth Board of Appeal of EUIPO of 18 July 2019 (Joined Cases R 1655/2018-4 and R 1723/2018-4), relating to revocation proceedings between Dermavita Co. and Allergan Holdings France. Operative part The Court: 1. Dismisses the action; 2. Orders Allergan Holdings France to pay the costs.